Previous 10 | Next 10 |
KalVista Pharmaceticals (NASDAQ: KALV ): Q4 GAAP EPS of -$0.37 beats by $0.28 . More news on: KalVista Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Virtual Healthcare Conference on Wednesday, April 15, ...
– Response to Coronavirus Impact on Ongoing Clinical Trials – – Cash Runway Extended into 2022 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small ...
The following slide deck was published by KalVista Pharmaceuticals, Inc. in conjunction with this Read more ...
KalVista Pharmaceticals (NASDAQ: KALV ): Q3 GAAP EPS of -$0.52 beats by $0.03 . Revenue of $1.58M (-59.4% Y/Y) misses by $9.91M . Press Release More news on: KalVista Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the SVB Leerink 9 th Annual Global Healthcare Conference on Tuesd...
– Merck Option Agreement Expires – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the option agreement between ...
– KVD900 Phase 2 Clinical Trial Data Anticipated in Q2 2020 – – KVD824 Selected for Prophylactic Treatment; Phase 2 Expected to Initiate in H2 2020 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the di...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...